膳食碳水化合物限制可增强2型糖尿病患者体重减轻对血糖控制和肝脏脂肪的改善:一项随机对照试验
该开放标签平行随机对照试验纳入72例2型糖尿病患者,比较6周等能量限制(目标约6%体重减轻)下低碳水高蛋白饮食(CRHP)与传统糖尿病饮食(CD)对血糖控制和肝脏脂肪的影响。结果显示两组体重均下降5.8 kg(5.9%),CRHP饮食较CD饮食进一步降低HbA1c、日间平均血糖和血糖变异系数,并增强空腹甘油三酯和肝脏脂肪含量的下降,但胰腺脂肪含量下降幅度较小。
要点
- 6周CRHP饮食较CD饮食进一步降低HbA1c达-1.9 mmol/mol(-0.18%),p=0.018。
- CRHP饮食增强空腹甘油三酯下降(-18%)和肝脏脂肪含量下降(-26%),后者p=0.051。
- CRHP饮食对胰腺脂肪含量的降低幅度小于CD饮食(33% vs CD,p=0.010)。
核心结论
- 在2型糖尿病患者中,与CD饮食相比,6周适度碳水化合物限制可适度改善血糖控制,并在体重减轻效应之外进一步降低循环和肝内甘油三酯水平。
- 蛋白质和脂肪摄入量及膳食宏量营养素质量的同期差异可能促成了这些结果,应在未来研究中探索。
研究设计与样本
- 开放标签、平行随机对照试验,纳入成人2型糖尿病患者,HbA1c 48-97 mmol/mol(6.5-11%),BMI>25 kg/m2,eGFR>30 ml min-1 [1.73 m]-2,降糖治疗限于二甲双胍或二肽基肽酶-4抑制剂。
- 参与者由第三方随机分配至6周能量限制(提供所有食物),目标约6%体重减轻,接受碳水化合物减少高蛋白饮食(CRHP,占总能量摄入百分比[E%]:碳水化合物30/蛋白质30/脂肪40)或传统糖尿病饮食(CD,E%:碳水化合物50/蛋白质17/脂肪33)。
- 数据在哥本哈根大学医院(Bispebjerg和Herlev)收集;主要结局为HbA1c变化,次要结局为循环和肝内甘油三酯变化。
主要发现
- 共纳入72例成人(CD 36例,CRHP 36例,均为白人,38例男性),2型糖尿病平均病程8年,平均HbA1c 57 mmol/mol(7.4%),平均BMI 33 kg/m2;67例完成研究(CD 33例,CRHP 34例)。
- 6周后两组体重均下降5.8 kg(5.9%)。
- 与CD饮食相比,CRHP饮食进一步降低HbA1c(均值[95%CI] -1.9 [-3.5, -0.3] mmol/mol [-0.18 (-0.32, -0.03)%],p=0.018)和日间平均血糖(均值[95%CI] -0.8 [-1.2, -0.4] mmol/l,p<0.001)。
- CRHP饮食通过降低血糖变异系数稳定血糖波动(均值[95%CI] -4.1 [-5.9, -2.2]%,p<0.001),并增强空腹甘油三酯浓度下降(均值[95%CI] -18 [-29, -6]%,p<0.01)和肝脏脂肪含量下降(均值[95%CI] -26 [-45, 0]%,p=0.051)。
- CRHP饮食对胰腺脂肪含量的降低幅度小于CD饮食(均值[95%CI] 33 [7, 65]%,p=0.010);两种饮食均显著且相似地降低空腹血糖、胰岛素、HOMA2-IR和胆固醇浓度(总、LDL和HDL)。
关键数值与推荐
- CRHP饮食E%:碳水化合物30/蛋白质30/脂肪40;CD饮食E%:碳水化合物50/蛋白质17/脂肪33。
- HbA1c变化为主要结局;循环和肝内甘油三酯变化为次要结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Lifestyle modification and weight loss are cornerstones of type 2 diabetes management. However, carbohydrate restriction may have weight-independent beneficial effects on glycaemic control. This has been difficult to demonstrate because low-carbohydrate diets readily decrease body weight. We hypothesised that carbohydrate restriction enhances the beneficial metabolic effects of weight loss in type 2 diabetes. METHODS: This open-label, parallel RCT included adults with type 2 diabetes, HbA1c 48-97 mmol/mol (6.5-11%), BMI >25 kg/m2, eGFR >30 ml min-1 [1.73 m]-2 and glucose-lowering therapy restricted to metformin or dipeptidyl peptidase-4 inhibitors. Participants were randomised by a third party and assigned to 6 weeks of energy restriction (all foods were provided) aiming at ~6% weight loss with either a carbohydrate-reduced high-protein diet (CRHP, percentage of total energy intake [E%]: CH30/P30/F40) or a conventional diabetes diet (CD, E%: CH50/P17/F33). Fasting blood samples, continuous glucose monitoring and magnetic resonance spectroscopy were used to assess glycaemic control, lipid metabolism and intrahepatic fat. Change in HbA1c was the primary outcome; changes in circulating and intrahepatic triacylglycerol were secondary outcomes. Data were collected at Copenhagen University Hospital (Bispebjerg and Herlev). RESULTS: Seventy-two adults (CD 36, CRHP 36, all white, 38 male sex) with type 2 diabetes (mean duration 8 years, mean HbA1c 57 mmol/mol [7.4%]) and mean BMI of 33 kg/m2 were enrolled, of which 67 (CD 33, CRHP 34) completed the study. Body weight decreased by 5.8 kg (5.9%) in both groups after 6 weeks. Compared with the CD diet, the CRHP diet further reduced HbA1c (mean [95% CI] -1.9 [-3.5, -0.3] mmol/mol [-0.18 (-0.32, -0.03)%], p = 0.018) and diurnal mean glucose (mean [95% CI] -0.8 [-1.2, -0.4] mmol/l, p < 0.001), stabilised glucose excursions by reducing glucose CV (mean [95% CI] -4.1 [-5.9, -2.2]%, p < 0.001), and augmented the reductions in fasting triacylglycerol concentration (by mean [95% CI] -18 [-29, -6]%, p < 0.01) and liver fat content (by mean [95% CI] -26 [-45, 0]%, p = 0.051). However, pancreatic fat content was decreased to a lesser extent by the CRHP than the CD diet (mean [95% CI] 33 [7, 65]%, p = 0.010). Fasting glucose, insulin, HOMA2-IR and cholesterol concentrations (total, LDL and HDL) were reduced significantly and similarly by both diets. CONCLUSIONS/INTERPRETATION: Moderate carbohydrate restriction for 6 weeks modestly improved glycaemic control, and decreased circulating and intrahepatic triacylglycerol levels beyond the effects of weight loss itself compared with a CD diet in individuals with type 2 diabetes. Concurrent differences in protein and fat intakes, and the quality of dietary macronutrients, may have contributed to these results and should be explored in future studies. TRIAL REGISTRATION: ClinicalTrials.gov NCT03814694. FUNDING: The study was funded by Arla Foods amba, The Danish Dairy Research Foundation, and Copenhagen University Hospital Bispebjerg Frederiksberg.
引用
- Thomsen MN, Skytte MJ, Samkani A, et al. Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial. Diabetologia. 2022. PMID: 34993571. doi:10.1007/s00125-021-05628-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。